Your browser doesn't support javascript.
loading
Time-Driven Activity-Based Costing for Capturing the Complexity of Healthcare Processes: The Case of Deep Vein Thrombosis and Leg Ulcers.
Rognoni, Carla; Furnari, Alessandro; Lugli, Marzia; Maleti, Oscar; Greco, Alessandro; Tarricone, Rosanna.
Afiliación
  • Rognoni C; Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, 20136 Milan, Italy.
  • Furnari A; Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, 20136 Milan, Italy.
  • Lugli M; National Reference Training Center in Phlebology (NRTCP), Vascular Surgery-Cardiovascular Department, Hesperia Hospital, 41125 Modena, Italy.
  • Maleti O; National Reference Training Center in Phlebology (NRTCP), Vascular Surgery-Cardiovascular Department, Hesperia Hospital, 41125 Modena, Italy.
  • Greco A; Outpatient Wound Care Centre, Local Health Care System, 03100 Frosinone, Italy.
  • Tarricone R; Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, 20136 Milan, Italy.
Article en En | MEDLINE | ID: mdl-37239543
ABSTRACT
Time-driven activity-based costing (TDABC) is suggested to assess costs within the value-based healthcare approach, but there is a paucity of applications in chronic diseases such as deep vein thrombosis (DVT) and leg ulcers. In this context, we applied TDABC in a cost-effectiveness analysis comparing venous stenting to compression ± anticoagulation (standard of care-SOC) from both hospital and societal perspectives in Italy. TDABC was applied to both treatments to assess costs that were included in a cost-effectiveness model. Clinical inputs were retrieved from the literature and integrated with real-world data. The Incremental Cost Utility Ratio (ICUR) of stenting compared to SOC was EUR 10,270/QALY and EUR 8962/QALY for hospital and societal perspectives, respectively. The mean cost per patient for venous stenting of EUR 5082 was higher than the Diagnosis-Related Group (DRG) reimbursement (EUR 4742). For SOC, an ulcer healing in 3 months costs EUR 1892, of which EUR 302 (16%) is borne by the patient versus a reimbursement of EUR 1132. TDABC showed that venous stenting may be cost-effective compared with SOC but that reimbursement rates may not completely cover the real costs, which are partially sustained by the patients. A more efficient policy for covering the real costs may be beneficial for both clinical centers and patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Asunto principal: Trombosis de la Vena / Úlcera de la Pierna Tipo de estudio: Health_economic_evaluation / Prognostic_studies Límite: Humans Idioma: En Revista: Int J Environ Res Public Health Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Asunto principal: Trombosis de la Vena / Úlcera de la Pierna Tipo de estudio: Health_economic_evaluation / Prognostic_studies Límite: Humans Idioma: En Revista: Int J Environ Res Public Health Año: 2023 Tipo del documento: Article País de afiliación: Italia
...